2020
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi.
Hsieh YL, Jahn A, Menzies NA, Yaesoubi R, Salomon JA, Girma B, Gunde L, Eaton JW, Auld A, Odo M, Kiyiika CN, Kalua T, Chiwandira B, Mpunga JU, Mbendra K, Corbett L, Hosseinipour MC, Cohen T, Kunkel A. Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 643-650. PMID: 33177475, PMCID: PMC8564780, DOI: 10.1097/qai.0000000000002497.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIPT programIPT strategyPreventive therapyContinuous isoniazid preventive therapyMore TB casesHIV-positive adultsCases of tuberculosisAnticipated health effectsComparable health benefitsHIV/AIDSCause deathAntiretroviral therapyTB casesTB controlTB incidenceDrug costsMalawi MinistryMean reductionTuberculosisMycobacterium tuberculosisTherapyAnticipated health impactsHealth effectsHealth benefits
2009
Extensively Drug‐Resistant Tuberculosis and HIV/AIDS
Murray M, Cohen T. Extensively Drug‐Resistant Tuberculosis and HIV/AIDS. 2009, 253-275. DOI: 10.1002/9783527627905.ch10.Peer-Reviewed Original Research